These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 36716415)

  • 1. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
    JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Harter P; Mouret-Reynier MA; Pignata S; Cropet C; González-Martín A; Bogner G; Fujiwara K; Vergote I; Colombo N; Nøttrup TJ; Floquet A; El-Balat A; Scambia G; Guerra Alia EM; Fabbro M; Schmalfeldt B; Hardy-Bessard AC; Runnebaum I; Pujade-Lauraine E; Ray-Coquard I
    Gynecol Oncol; 2022 Feb; 164(2):254-264. PubMed ID: 34952708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
    Ray-Coquard I; Leary A; Pignata S; Cropet C; González-Martín A; Marth C; Nagao S; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alia EM; Bogner G; Yoshida H; Lefeuvre-Plesse C; Buderath P; Mosconi AM; Lortholary A; Burges A; Medioni J; El-Balat A; Rodrigues M; Park-Simon TW; Dubot C; Denschlag D; You B; Pujade-Lauraine E; Harter P;
    Ann Oncol; 2023 Aug; 34(8):681-692. PubMed ID: 37211045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
    Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
    Labidi-Galy SI; Rodrigues M; Sandoval JL; Kurtz JE; Heitz F; Mosconi AM; Romero I; Denison U; Nagao S; Vergote I; Parma G; Nøttrup TJ; Rouleau E; Garnier G; El-Balat A; Zamagni C; Martín-Lorente C; Pujade-Lauraine E; Fiévet A; Ray-Coquard IL
    Ann Oncol; 2023 Feb; 34(2):152-162. PubMed ID: 36564284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the Homologous Recombination Repair Mutation Defined by a 15-Gene Panel Associated with the Prognosis of Epithelial Ovarian Cancer?
    Liu Y; Chen X; Lu H; Wu X; Liu X; Xu F; Ye D; Ding B; Lu X; Qiu L; Zhu J; Wang Y; Huang X; Shen Z; Zhu T; Shen Y; Zhou Y
    Mol Diagn Ther; 2024 Sep; 28(5):621-632. PubMed ID: 38967864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.
    Fujiwara K; Fujiwara H; Yoshida H; Satoh T; Yonemori K; Nagao S; Matsumoto T; Kobayashi H; Bourgeois H; Harter P; Mosconi AM; Vazquez IP; Reinthaller A; Fujita T; Rowe P; Pujade-Lauraine E; Ray-Coquard I
    J Gynecol Oncol; 2021 Sep; 32(5):e82. PubMed ID: 34378365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
    Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
    JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
    Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
    N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Lorusso D; Mouret-Reynier MA; Harter P; Cropet C; Caballero C; Wolfrum-Ristau P; Satoh T; Vergote I; Parma G; Nøttrup TJ; Lebreton C; Fasching PA; Pisano C; Manso L; Bourgeois H; Runnebaum I; Zamagni C; Hardy-Bessard AC; Schnelzer A; Fabbro M; Schmalfeldt B; Berton D; Belau A; Lotz JP; Gropp-Meier M; Gladieff L; Lück HJ; Abadie-Lacourtoisie S; Pujade-Lauraine E; Ray-Coquard I
    Int J Gynecol Cancer; 2024 Apr; 34(4):550-558. PubMed ID: 38129136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
    Boidot R; Blum MGB; Wissler MP; Gottin C; Ruzicka J; Chevrier S; Delhomme TM; Audoux J; Jeanniard A; Just PA; Harter P; Pignata S; González-Martin A; Marth C; Mäenpää J; Colombo N; Vergote I; Fujiwara K; Duforet-Frebourg N; Bertrand D; Philippe N; Ray-Coquard I; Pujade-Lauraine E;
    Eur J Cancer; 2024 May; 202():113978. PubMed ID: 38471290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
    Loverix L; Vergote I; Busschaert P; Vanderstichele A; Venken T; Boeckx B; Harter P; Brems H; Van Nieuwenhuysen E; Pignata S; Baert T; Gonzalez-Martin A; Han S; Marth C; Neven P; Colombo N; Berteloot P; Mäenpää J; Olbrecht S; Laga T; Sablon E; Ray-Coquard I; Pujade-Lauraine E; Lambrechts D; Van Gorp T
    Eur J Cancer; 2023 Jul; 188():131-139. PubMed ID: 37245441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
    González-Martín A; Desauw C; Heitz F; Cropet C; Gargiulo P; Berger R; Ochi H; Vergote I; Colombo N; Mirza MR; Tazi Y; Canzler U; Zamagni C; Guerra-Alia EM; Levaché CB; Marmé F; Bazan F; de Gregorio N; Dohollou N; Fasching PA; Scambia G; Rubio-Pérez MJ; Milenkova T; Costan C; Pautier P; Ray-Coquard I;
    Eur J Cancer; 2022 Oct; 174():221-231. PubMed ID: 36067615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.
    Christinat Y; Ho L; Clément S; Genestie C; Sehouli J; Cinieri S; Gonzalez Martin A; Denison U; Fujiwara K; Vergote I; Tognon G; Hietanen S; Ray-Coquard I; Pujade-Lauraine E; McKee TA
    JCO Precis Oncol; 2023 Jun; 7():e2200555. PubMed ID: 37364234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.
    Zhu Y; Liu K; Cao H; Zhu H
    J Ovarian Res; 2023 Aug; 16(1):168. PubMed ID: 37605274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
    Callens C; Rodrigues M; Briaux A; Frouin E; Eeckhoutte A; Pujade-Lauraine E; Renault V; Stoppa-Lyonnet D; Bieche I; Bataillon G; Karayan-Tapon L; Rochelle T; Heitz F; Cecere SC; Pérez MJR; Grimm C; Nøttrup TJ; Colombo N; Vergote I; Yonemori K; Ray-Coquard I; Stern MH; Popova T
    Oncogene; 2023 Nov; 42(48):3556-3563. PubMed ID: 37945748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
    Sabatier R; Rousseau F; Joly F; Cropet C; Montégut C; Frindte J; Cinieri S; Guerra Alía EM; Polterauer S; Yoshida H; Vergote I; Colombo N; Hietanen S; Largillier R; Canzler U; Gratet A; Marmé F; Favier L; Pujade-Lauraine E; Ray-Coquard I
    Eur J Cancer; 2023 Mar; 181():42-52. PubMed ID: 36634389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
    Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M
    Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
    Paik J
    Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
    Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
    Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.